Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
20.83
+0.17 (0.82%)
At close: Jun 26, 2026, 4:00 PM EDT
20.84
+0.01 (0.05%)
Pre-market: Jun 29, 2026, 8:46 AM EDT
Kailera Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A comprehensive obesity-focused pipeline is advancing, led by ribupatide in both injectable and oral forms, with multiple pivotal trials underway and key data readouts expected through 2028. Strategic collaborations, robust financials, and differentiated clinical designs position the franchise for commercial and clinical impact.